Cytokinetics, Incorporated (CYTK): Price and Financial Metrics

Cytokinetics, Incorporated (CYTK): $29.46

1.34 (-4.35%)

POWR Rating

Component Grades








Add CYTK to Watchlist
Sign Up

Industry: Biotech




#221 of 356

in industry

CYTK Price/Volume Stats

Current price $29.46 52-week high $52.40
Prev. close $30.80 52-week low $28.96
Day low $29.25 Volume 1,689,200
Day high $31.09 Avg. volume 893,801
50-day MA $33.07 Dividend yield N/A
200-day MA $37.48 Market Cap 2.83B

CYTK Stock Price Chart Interactive Chart >


  • Growth is the dimension where CYTK ranks best; there it ranks ahead of 48.86% of US stocks.
  • The strongest trend for CYTK is in Growth, which has been heading up over the past 177 days.
  • CYTK ranks lowest in Sentiment; there it ranks in the 15th percentile.

CYTK Stock Summary

  • With a price/sales ratio of 298.55, CYTOKINETICS INC has a higher such ratio than 98.75% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -5.48 for CYTOKINETICS INC; that's greater than it is for only 3.23% of US stocks.
  • As for revenue growth, note that CYTK's revenue has grown -93.42% over the past 12 months; that beats the revenue growth of merely 1.27% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to CYTOKINETICS INC, a group of peers worth examining would be FULC, ADVM, LYRA, SAGE, and BPMC.
  • Visit CYTK's SEC page to see the company's official filings. To visit the company's web site, go to

CYTK Valuation Summary

  • In comparison to the median Healthcare stock, CYTK's price/sales ratio is 15610.53% higher, now standing at 298.5.
  • Over the past 236 months, CYTK's price/earnings ratio has gone up 7.3.

Below are key valuation metrics over time for CYTK.

Stock Date P/S P/B P/E EV/EBIT
CYTK 2023-09-22 298.5 -8.9 -5.5 -7.1
CYTK 2023-09-21 301.3 -9.0 -5.6 -7.2
CYTK 2023-09-20 308.4 -9.2 -5.7 -7.3
CYTK 2023-09-19 317.6 -9.5 -5.9 -7.5
CYTK 2023-09-18 326.7 -9.8 -6.0 -7.7
CYTK 2023-09-15 330.2 -9.9 -6.1 -7.8

CYTK Growth Metrics

    The 3 year cash and equivalents growth rate now stands at 192.88%.
  • Its 4 year net cashflow from operations growth rate is now at -380.62%.
  • Its 3 year net cashflow from operations growth rate is now at -42.21%.
Over the past 33 months, CYTK's revenue has gone up $121,363,000.

The table below shows CYTK's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 148.231 -246.063 -282.145
2022-06-30 151.153 -200.793 -215.921
2022-03-31 65.028 -139.814 -257.655
2021-12-31 70.428 -142.522 -215.314
2021-09-30 21.55 -45.635 -228.674
2021-06-30 57.801 7.502 -155.763

CYTK's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CYTK has a Quality Grade of C, ranking ahead of 30.43% of graded US stocks.
  • CYTK's asset turnover comes in at 0.108 -- ranking 258th of 682 Pharmaceutical Products stocks.
  • VRTX, INBP, and MBIO are the stocks whose asset turnover ratios are most correlated with CYTK.

The table below shows CYTK's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.108 1 -0.236
2021-03-31 0.129 1 -0.244
2020-12-31 0.149 1 -0.286
2020-09-30 0.173 1 -0.292
2020-06-30 0.077 1 -0.445
2020-03-31 0.095 1 -0.461

CYTK Price Target

For more insight on analysts targets of CYTK, see our CYTK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $44.80 Average Broker Recommendation 1.5 (Moderate Buy)

Cytokinetics, Incorporated (CYTK) Company Bio

Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The company was founded in 1997 and is based in South San Francisco, California.

CYTK Latest News Stream

Event/Time News Detail
Loading, please wait...

CYTK Latest Social Stream

Loading social stream, please wait...

View Full CYTK Social Stream

Latest CYTK News From Around the Web

Below are the latest news stories about CYTOKINETICS INC that investors may wish to consider to help them evaluate CYTK as an investment opportunity.

Cytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program

Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 1st, 2023 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the sixth annual Cytokinetics Communications Grant Program. The program will award five grants in the amount of $20,000 each to patient advocacy or

Yahoo | September 28, 2023

EVP Research & Development Fady Malik Sells 2,500 Shares of Cytokinetics Inc

On September 14, 2023, Fady Malik, the Executive Vice President of Research & Development at Cytokinetics Inc (NASDAQ:CYTK), sold 2,500 shares of the company.

Yahoo | September 15, 2023

Insider Sell: Cytokinetics Inc's President & CEO Robert Blum Sells 12,500 Shares

On September 13, 2023, Robert Blum, President & CEO of Cytokinetics Inc (NASDAQ:CYTK), sold 12,500 shares of the company.

Yahoo | September 14, 2023

The 3 Best Mid-Cap Stocks to Buy Now: September 2023

With the best mid-cap stocks to buy, investors get the best of both worlds: an established business but with ample room to grow.

Josh Enomoto on InvestorPlace | September 7, 2023

Cytokinetics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in September: Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023 at 8:00 AM Eastern Time in a fireside chat with Robert I. Blum, President and Chief Executive Officer, and Fady I. Malik, Executive Vice President of Research & Development, at the Sheraton New Y

Yahoo | September 7, 2023

Read More 'CYTK' Stories Here

CYTK Price Returns

1-mo -18.17%
3-mo N/A
6-mo -18.53%
1-year -39.20%
3-year 22.80%
5-year 217.12%
YTD -35.70%
2022 0.53%
2021 119.35%
2020 95.85%
2019 67.88%
2018 -22.45%

Continue Researching CYTK

Want to see what other sources are saying about Cytokinetics Inc's financials and stock price? Try the links below:

Cytokinetics Inc (CYTK) Stock Price | Nasdaq
Cytokinetics Inc (CYTK) Stock Quote, History and News - Yahoo Finance
Cytokinetics Inc (CYTK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!